

Investigation Report on China's Irbesartan Market, 2018-2022

<https://marketpublishers.com/r/I21BB425991EN.html>

Date: September 2018

Pages: 30

Price: US\$ 2,200.00 (Single User License)

ID: I21BB425991EN

Abstracts

Description

Sartans are antihypertensive drugs with highly selective, effective and long-lasting multi-organ targeted protection. With a more specific mechanism of action, they prevent dry cough and other side effects that may be caused by angiotensin-converting enzyme inhibitors (ACEIs), and thus have replaced the ACEIs in some clinical uses. As a result, the growth of the ACEI market slows down, which leading to a steady increase in the Sartans market. Another growth driver is the new edition of List of Medicines Covered by National Basic Medical Insurance that included compound preparations.

Irbesartan was developed by Sanofi, first approved by the European Medicines Agency (EMA) on Aug. 27, 1997, and then approved by the U.S. Food and Drug Administration (FDA) on Sept. 30, 1997. The trade name of Sanofi's Irbesartan is Aprovel. Irbesartan is mainly used to treat primary hypertension and has little effect on heart rate. Irbesartan can also protect kidneys and slow the progression of diabetic nephropathy. It can slow the progression of kidney disease for patients with both type 2 diabetic nephropathy and hypertension.

According to CRI, domestic enterprises developed the generic versions of Aprovel early. The generic drugs were approved to be sold in China in 2000. By Sept. 2018, there are 11 Irbesartan API manufacturers, and 24 manufacturers of Irbesartan tablets, capsules and dispersible tablets in China. The Irbesartan products of Sanofi and its subsidiary Sanofi (Hangzhou) Pharmaceutical Co., Ltd. have an absolute advantage in China, taking up approximately 80% market share by sales value in 2017.

There were about 330 million hypertensive patients in China at the end of 2017. One in

every three adults has high blood pressure. Chinese hypertensive patients account for about one-third of the global total. The incidence of hypertension in China rose by 32.1% from 5.1% in 1959 to 37.2% in 2017.

The sales value of Irbesartan was on the rise after it entered China, exceeding CNY 300 million in 2017. It is expected that the market size will continue to grow from 2018 to 2022 with the increasing number of hypertensive patients.

Topics Covered:

Development environment of China's Irbesartan market

Market demand for Irbesartan in China

Analysis on competition on China's Irbesartan market

Analysis on major Irbesartan manufacturers in China

Driving forces for China's Irbesartan market from 2018 to 2022

Prospect of China's Irbesartan market from 2018 to 2022

Contents

1 RELEVANT CONCEPTS OF IRBESARTAN

- 1.1 Indications for Irbesartan
- 1.2 Development History of Irbesartan in China
- 1.3 Governmental Approval of Irbesartan in China

2 SALES OF IRBESARTAN IN CHINA, 2013-2017

- 2.1 Sales Value
 - 2.1.1 Overall Sales Value
 - 2.1.2 Sales Value by Region
- 2.2 Sales Volume
 - 2.2.1 Overall Sales Volume
 - 2.2.2 Sales Volume by Region
- 2.3 Sales of Irbesartan by Dosage Form in China, 2013-2017
 - 2.3.1 Tablets
 - 2.3.2 Capsules

3 ANALYSIS ON MAJOR COMPETITORS ON CHINA'S IRBESARTAN MARKET, 2013-2017

- 3.1 Analysis on Market Share of Major Irbesartan Manufacturers
 - 3.1.1 Market Share by Sales Value
 - 3.1.2 Market Share by Sales Volume
- 3.2 Sanofi (Hangzhou) Pharmaceutical Co., Ltd.
 - 3.2.1 Enterprise Profile
 - 3.2.2 Sales of Sanofi (Hangzhou) Pharmaceutical Co., Ltd.'s Irbesartan in China⁹
- 3.3 Sanofi
 - 3.3.1 Enterprise Profile
 - 3.3.2 Sales of Sanofi's Irbesartan in China
- 3.4 Jiangsu Hengrui Medicine Co., Ltd.
 - 3.4.1 Enterprise Profile
 - 3.4.2 Sales of Jiangsu Hengrui Medicine Co., Ltd.'s Irbesartan in China
- 3.5 Zhuhai Rundu Pharmaceutical Co., Ltd.
- 3.6 Weifang Zhongshi Pharmaceutical Co., Ltd.

4 PRICES OF IRBESARTAN IN CHINA, 2017-2018

- 4.1 Sanofi (Hangzhou) Pharmaceutical Co., Ltd. (Aprovel)
- 4.2 Sanofi (Aprovel)
- 4.3 Jiangsu Hengrui Medicine Co., Ltd. (Jijia)
- 4.4 Zhuhai Rundu Pharmaceutical Co., Ltd. (Yitaiqing)
- 4.5 Weifang Zhongshi Pharmaceutical Co., Ltd. (Bida)

5 PROSPECT OF CHINA'S IRBESARTAN MARKET, 2018-2022

- 5.1 Forecast on Market Size
- 5.2 Forecast on Market Trend

Selected Charts

SELECTED CHARTS

Chart Sales of Irbesartan in China, 2013-2017

Chart Sales Value of Irbesartan in Parts of China, 2013-2017

Chart Sales Volume of Irbesartan in China, 2013-2017

Chart Sales Volume of Irbesartan in Parts of China, 2013-2017

Chart Sales Value of Irbesartan Tablets in China, 2013-2017

Chart Sales Value of Irbesartan Capsules in China, 2013-2017

Chart Market Share of Top 5 Irbesartan Manufacturers by Sales Value in China, 2013-2017

Chart Market Share of Top 5 Irbesartan Manufacturers by Sales Volume in China, 2013-2017

Chart Profile of Sanofi (Hangzhou) Pharmaceutical Co., Ltd.

Chart Sales Value of Sanofi (Hangzhou) Pharmaceutical Co., Ltd.'s Irbesartan, 2013-2017

Chart Profile of Sanofi

Chart Sales Value of Sanofi's Irbesartan in China, 2013-2017

Chart Sales Value of Jiangsu Hengrui Medicine Co., Ltd.'s Irbesartan, 2013-2017

Chart Prices of Sanofi (Hangzhou) Pharmaceutical Co., Ltd.'s Irbesartan in Parts of China, 2017-2018

Chart Prices of Sanofi's Irbesartan in Parts of China, 2017-2018

Chart Prices of Jiangsu Hengrui Medicine Co., Ltd.'s Irbesartan in Parts of China, 2017-2018

Chart Forecast on Sales Value of Irbesartan in China, 2018-2012

I would like to order

Product name: Investigation Report on China's Irbesartan Market, 2018-2022

Product link: <https://marketpublishers.com/r/l21BB425991EN.html>

Price: US\$ 2,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l21BB425991EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970